Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422910 | 1.00 | SRD5A2 (0.50) | SRD5A2PLA2G4BNR1H3LMNAMAPK1 | |
| SCHEMBL5423767 | 0.92 | NR1H3 (0.52) | PLA2G4BNR1H3LMNAMAPK1L3MBTL1 | |
| SCHEMBL5423760 | 0.92 | NR1H3 (0.52) | PLA2G4BNR1H3LMNAMAPK1L3MBTL1 | |
| SCHEMBL5414621 | 0.92 | PPARG (0.51) | SRD5A2PLA2G4BNR1H3LMNAMAPK1 | |
| SCHEMBL5427796 | 0.92 | PPARG (0.51) | SRD5A2PLA2G4BNR1H3LMNAMAPK1 | |
| SCHEMBL5414627 | 0.92 | PPARG (0.51) | SRD5A2PLA2G4BNR1H3LMNAMAPK1 | |
| SCHEMBL5419304 | 0.90 | PLA2G4B (0.47) | SRD5A2PLA2G4BNR1H3LMNAMAPK1 | |
| SCHEMBL5426918 | 0.90 | PLA2G4B (0.47) | SRD5A2PLA2G4BNR1H3LMNAMAPK1 | |
| SCHEMBL5419296 | 0.90 | PLA2G4B (0.47) | SRD5A2PLA2G4BNR1H3LMNAMAPK1 | |
| SCHEMBL5426924 | 0.90 | PLA2G4B (0.47) | SRD5A2PLA2G4BNR1H3LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167490-A1 | Imino ether derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO LTD | 2007-07-19 | — | — | US | disclosed |
| EP-1602642-A1 | IMINO ETHER DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167490-A1 | Imino ether derivative compounds and drugs containing the compounds as the active ingredient | INSR, NR1H2, NR1H3 | SRD5A2 76/4885PLA2G4B 2091/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.